| Fernando Jose Teixeira, | |
|
2823 Fresno St, Fresno, CA 93721-1324 | |
| (559) 499-6440 | |
| Not Available |
| Full Name | Fernando Jose Teixeira |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 2823 Fresno St, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821551342 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | C161342 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Regional Medical Center | Fresno, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Faculty Associates Inc | 6507181708 | 257 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.
A toxic chemical found in contaminated cough syrup suspected to have caused the deaths of 22 people in Panama, has now been found in three more medications made by a government-run factory in Panama.
ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
A study by researchers at Kaiser Permanente in Denver, Colorado evaluated the stability of thyroid stimulating hormone (TSH) in patients using synthetic medication versus those using desiccated thyroid products to treat hypothyroidism.
› Verified 6 days ago
| Entity Name | University Faculty Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073911137 PECOS PAC ID: 6507181708 Enrollment ID: O20150211000164 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.
A toxic chemical found in contaminated cough syrup suspected to have caused the deaths of 22 people in Panama, has now been found in three more medications made by a government-run factory in Panama.
ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
A study by researchers at Kaiser Permanente in Denver, Colorado evaluated the stability of thyroid stimulating hormone (TSH) in patients using synthetic medication versus those using desiccated thyroid products to treat hypothyroidism.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fernando Jose Teixeira, 2625 E Divisadero St, Fresno, CA 93721-1431 Ph: (559) 443-2682 | Fernando Jose Teixeira, 2823 Fresno St, Fresno, CA 93721-1324 Ph: (559) 499-6440 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.
A toxic chemical found in contaminated cough syrup suspected to have caused the deaths of 22 people in Panama, has now been found in three more medications made by a government-run factory in Panama.
ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.
GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
A study by researchers at Kaiser Permanente in Denver, Colorado evaluated the stability of thyroid stimulating hormone (TSH) in patients using synthetic medication versus those using desiccated thyroid products to treat hypothyroidism.
› Verified 6 days ago
Michelle Lea Storkan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 | |
Harminder S Longia, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2615 E Clinton Ave, Fresno, CA 93703 Phone: 559-225-6100 | |
Dr. Jessie Werner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 | |
Megann Forrest Young, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 Fax: 559-499-6441 | |
Geoffrey R Stroh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 Fax: 559-499-6441 | |
Marc Stanley Shalit, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6439 Fax: 559-499-6441 | |
Dr. Patil Armenian, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 |